eVOLVE-Lung02: A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT05984277

Contact name

Laura Morse Cucci

Clinical trials study type

Oncology - Pulmonary

Clinical trials trial status

Open to Accrual

IRB number

2218080

Principal investigator

Mei Tang, MD

Clinical trials study number

D798AC00001 (G2404)

Phone

443-849-3122

Clinical trials title (full)

eVOLVE-Lung02: A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.